Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2111-2120

  Li, Li'an ^a   Huang, Ke ^a   You, Yanqin ^a   Fu, Xiaoyu ^a   Hu, Lingyun ^a   Song, Lei ^a   Meng, Yuanguang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; Epithelial ovarian cancer; Hypoxia inducible factor 1 ; miR 210; Tyrosine protein phosphatase non receptor type 1

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA 210; PHOSPHATASE; PHOSPHATASE NON RECEPTOR TYPE 1; UNCLASSIFIED DRUG; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN TYROSINE PHOSPHATASE 1B; HIF1A PROTEIN, HUMAN; MICRORNA; MIRN210 MICRORNA, HUMAN; OXYGEN; PTPN1 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; MIDDLE AGED; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME; UPREGULATION; DOWN REGULATION; CELL HYPOXIA; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OXYGEN; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1;

EID: 84899559247     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2368     Document Type: Article

References (64)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Colombo N, Van Gorp T, Parma G, et al: Ovarian cancer. Crit Rev Oncol Hematol 60: 159-179, 2006.
3. Moss C and Kaye SB: Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 38: 1701-1707, 2002.
4. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001.
5. Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999.
6. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
7. Cummins EP and Taylor CT: Hypoxia-responsive transcription factors. Pflugers Arch 450: 363-371, 2005.
8. Licausi F, Weits DA, Pant BD, Scheible WR, Geigenberger P and van Dongen JT: Hypoxia responsive gene expression is mediated by various subsets of transcription factors and miRNAs that are determined by the actual oxygen availability. New Phytol 190: 442-456, 2011.
9. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
10. Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
11. 2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
12. Pouyssegur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443, 2006.
13. Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
14. Blancher C, Moore JW, Talks KL, Houlbrook S and Harris AL: Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60: 7106-7113, 2000.
15. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
16. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
17. Pralhad T, Madhusudan S and Rajendrakumar K: Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 55: 1045-1053, 2003.
18. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
19. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: S62-S67, 2002.
20. Chi JT, Wang Z, Nuyten DS, et al: Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47, 2006.
21. Imai T, Horiuchi A, Wang C, et al: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163: 1437-1447, 2003.
22. Horiuchi A, Imai T, Shimizu M, et al: Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res 22: 2697-2702, 2002.
23. Horiuchi A, Hayashi T, Kikuchi N, et al: Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1alpha to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. Int J Cancer 131: 1755-1767, 2012.
24. Osada R, Horiuchi A, Kikuchi N, et al: Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38: 1310-1320, 2007.
25. Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113: 673-676, 2003.
26. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
27. Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113: 25-36, 2003.
28. Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
29. Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 26: 293-300, 2007.
30. Yu SL, Chen HY, Yang PC and Chen JJ: Unique microRNA signature and clinical outcome of cancers. DNA Cell Biology 26: 283-292, 2007.
31. Qiang R, Wang F, Shi LY, et al: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol 43: 632-641, 2011.
32. Au Yeung CL, Tsang TY, Yau PL and Kwok TT: Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/ urokinase-type plasminogen activator pathway. Oncogene 30: 2401-2410, 2011.
33. Xu CX, Xu M, Tan L, et al: MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem 287: 34970-34978, 2012.
34. Ye G, Fu G, Cui S, et al: MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 124: 359-368, 2011.
35. Vecchione A, Belletti B, Lovat F, et al: A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA 110: 9845-9850, 2013.
36. Mutharasan RK, Nagpal V, Ichikawa Y and Ardehali H: microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol 301: H1519-H1530, 2011.
37. Biswas S, Roy S, Banerjee J, et al: Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA 107: 6976-6981, 2010.
38. Merlo A, de Quiros SB, Secades P, et al: Identification of a signaling axis HIF-1alpha/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. J Clin Endocrinol Metab 97: E2194-E2200, 2012.
39. Wang H, Bian S and Yang CS: Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 32: 1881-1889, 2011.
40. Camps C, Buffa FM, Colella S, et al: hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348, 2008.
41. Gou D, Ramchandran R, Peng X, et al: miR-210 has an anti-apoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol 303: L682-L691, 2012.
42. Fasanaro P, D'Alessandra Y, Di Stefano V, et al: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 283: 15878-15883, 2008.
43. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
44. Kim SW, Li Z, Moore PS, et al: A sensitive non-radioactive northern blot method to detect small RNAs. Nucleic Acids Res 38: e98, 2010.
45. Greijer AE and van der Wall E: The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57: 1009-1014, 2004.
46. Carmeliet P, Dor Y, Herbert JM, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998.
47. Moritz W, Meier F, Stroka DM, et al: Apoptosis in hypoxic human pancreatic islets correlates with HIF-1alpha expression. FASEB J 16: 745-747, 2002.
48. Zhu P, Ning Y, Yao L, Chen M and Xu C: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res 29: 124, 2010.
49. Sangwan V, Paliouras GN, Cheng A, Dube N, Tremblay ML and Park M: Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. J Biol Chem 281: 221-228, 2006.
50. Gonzalez-Rodriguez A, Escribano O, Alba J, Rondinone CM, Benito M and Valverde AM: Levels of protein tyrosine phosphatase 1B determine susceptibility to apoptosis in serum-deprived hepatocytes. J Cell Physiol 212: 76-88, 2007.
51. Gu F, Nguyen DT, Stuible M, Dube N, Tremblay ML and Chevet E: Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem 279: 49689-49693, 2004.
52. Akasaki Y, Liu G, Matundan HH, et al: A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem 281: 6165-6174, 2006.
53. Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis 33: 1126-1133, 2012.
54. Dahiya N and Morin PJ: MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 17: F77-F89, 2010.
55. Shih KK, Qin LX, Tanner EJ, et al: A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol 121: 444-450, 2011.
56. Giannakakis A, Sandaltzopoulos R, Greshock J, et al: miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7: 255-264, 2008.
57. Tsuchiya S, Fujiwara T, Sato F, et al: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 286: 420-428, 2011.
58. Li T, Cao H, Zhuang J, et al: Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta 412: 66-70, 2011.
59. Puissegur MP, Mazure NM, Bertero T, et al: miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18: 465-478, 2011.
60. Ramon LA, Braza-Boils A, Gilabert J, et al: microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod 27: 3036-3045, 2012.
61. Chen WY, Liu WJ, Zhao YP, et al: Induction, modulation and potential targets of miR-210 in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int 11: 319-324, 2012.
62. Favaro E, Ramachandran A, McCormick R, et al: MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 5: e10345, 2010.
63. Nakada C, Tsukamoto Y, Matsuura K, et al: Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol 224: 280-288, 2011.
64. Noman MZ, Buart S, Romero P, et al: Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 72: 4629-4641, 2012.